Abstract: Systems, treatment and prognostic methods, and kits for risk stratification and development of treatment options for diffuse large B-cell lymphoma patients. The systems, methods, and kits comprise determining, detecting, and evaluating gene expression values for at least ALDOC, ASIP, ATP8A1, CD IE, DUSP16, FAF1, FAM223A1FAM223B, GAREM, GNG8, LM02, LPPR4, LY75, NMAEL, PAD 12, PDK1, PPP1R7, SCN1A, SLAMF1, SSTR2, TNFRSF9, USH2A, VEZF1, WDR91, ADRA2B, ECT2, ELOVL6, IGSF9, NEK3, PDK4, PES1, PUSL1, TAD A2A, and ZMYND19, or a subset thereof, detected in a biological sample from the patient and determining a risk score associated with the gene signature panel, which can be used to guide treatment of the patient.